Photoof Erman Akkus from X
May 31, 2024, 15:03
CheckMate 648 review by Erman Akkus
Erman Akkus, Medical Oncologist at Ankara University, shared on X:
“First line Nivolumab plus ChT / Nivolumab plus ipilimumab vs only ChT in advanced esophageal SCC.
CheckMate 648, 29-month follow-up: .
- Both IO combination provided better OS
- Nivo-ChT vs ChT
- PD-L1 ≥1%: HR=0.59 (0.46–0.76)
- Overall population: HR = 0.78 (0.65–0.93)
- Nivo-Ipi vs ChT PD-L1 ≥1%: HR = 0.62 (0.48–0.80)
- Overall population: HR = 0.77 (0.65–0.92)
- Grade 3–4 AEs: 49% vs 32% vs 36%”
Source: Erman Akkus/X